The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...
The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless ...
The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...
Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...
ZetaMet™ (Zeta-BC-003) is a synthetic, small-molecule, delivered via a proprietary controlled- release carrier intended to resolve metastatic breast cancer bone lesions, inhibit pain while ...
Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...
At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending ...
The president-elect’s choice of Robert F. Kennedy Jr., a vaccine skeptic who wants to disrupt U.S. health agencies, sent ...
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
The president-elect has said he’ll let Robert F. Kennedy Jr. “go wild” on healthcare, while many expect a leadership change ...
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback